Brought to you by 
Takeda launches Outpost Medicine, grants rights to urinary incontinence compound; development stops
16 Nov 2017
Executive Summary
Together with Frazier Healthcare Partners, Takeda Pharmaceutical Co. Ltd. launched a new company, Outpost Medicine, and granted the start-up exclusive global rights to its stress urinary incontinence project TAK233 (which Outpost renamed OP233).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda launches Outpost Medicine, grants rights to urinary incontinence compound; development stops
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice